Cite Filings / SLN / 0001104659-25-038392
Feed Companies Filings Check
Sign in
SCHEDULE 13D/A

Beneficial Ownership Report

Silence Therapeutics plc · Filed 2025-04-24 · Acc 0001104659-25-038392

Documents 1

  • SCHEDULE 13D/A Beneficial Ownership Report , xslSCHEDULE_13D_X01/primary_doc.xml

Around this filing

  • 2025-05-08 SCHEDULE 13D/A Beneficial Ownership Report
  • 2025-04-30 4 Options or other derivatives
  • 2025-04-28 4 Options or other derivatives
  • 2025-04-24 SCHEDULE 13D/A Beneficial Ownership Report
  • 2025-04-24 4 Options or other derivatives
  • 2025-04-22 4 Options or other derivatives
  • 2025-03-31 SCHEDULE 13D/A Beneficial Ownership Report

Link to a passage

At least 12 characters, not counting spaces, so the link points to one passage.

External

  • SEC EDGAR (opens in new tab)

Stakes reported in this filing

Stake history · largest stake in each 13D and 13G

  1. 2026-11-16 SCHEDULE 13G/A · TCG Crossover GP I, LLC 3.9%
  2. 2026-11-12 SCHEDULE 13G/A · Raymond Debbane 4.6%
  3. 2026-11-05 SCHEDULE 13G · FMR LLC 7.1%
  4. 2026-10-13 SCHEDULE 13G/A · Tetragon Financial Group Limited 5.3%
  5. 2026-10-13 SCHEDULE 13G · Tetragon Financial Group Limited 5.2%
  6. 2026-08-13 SCHEDULE 13G/A · Raymond Debbane 7.0%
  7. 2026-08-13 SCHEDULE 13D/A · Richard Griffiths 7.97%
Loading xslSCHEDULE_13D_X01/primary_doc.xml…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…